

Improving access to automated red cell exchange in sickle cell disease



Sasha Wilson: NHSBT TAS Education & Governance Lead
Abby Faver: NHSBT TAS Senior Nurse Manager

Objectives

- ◆ NHSBT Therapeutic Apheresis Services (TAS) is a national service delivering care to adults and children with sickle cell disease (SCD).
- ◆ We plan to share our perspectives on how access to automated red cell exchange might be improved.
- ◆ First by giving an overview of the context; Why do we need to improve access to automated red cell exchange for patients with sickle cell?
- ◆ Next we will give an overview of how our service is delivered, to optimise access for our sickle cell patients.

PLAN



Why do we need to improve access to automated red cell exchange?

- ◆ In the UK, around 15,000 people have sickle cell disease (SCD) & more than 300 babies are born each year with the condition.
- ◆ Greater use of automated red cell exchange transfusion benefits patients by -
 - ◆ Reducing complications of SCD
 - ◆ Reducing cost of iron chelation treatment
 - ◆ Improving patient access and experience



Manual vs Automated Red Cell Exchange

	Top-up transfusion	Manual exchange	Automated exchange
Staffing and training	Basic	Moderate	High
Frequency	3-4 weekly	3-4 weekly	4-8 weekly
Length of procedure	4-6 hours	2-4 hours (up to 4-8 if acute, previously untransfused)	2 hours
Units of red cells	2-3	3-6	8-10
Volume shifts	Large	Minimal/Moderate	Minimal
Ability to predict HbS% and Hb post transfusion	Moderate	Moderate	Very accurate
Iron loading (long term use)	High	Moderate	Minimal


Guidelines and Standards

Sickle Standards 2018, NHS England haemoglobinopathy service review

- All patients with sickle cell disease (SCD) should have access to specialised care regardless of geographical location
- Automated exchange transfusion should be available to all patients SCD
- Patients should have access to 24/7 care as standard



- Transfusion in Sickle Cell Disease Parts I&II (Davis et al 2016)
- Management of Acute Chest Syndrome in sickle cell disease (Howard et al 2015)
- Clinical Use of Apheresis Procedures (Howell et al, 2015)



Guidelines and Standards

NICE National Institute for Health and Care Excellence Medical technologies guidance 2016

- The case for adopting Spectra Optia for automated red blood cell exchange in patients with sickle cell disease is supported by the evidence.
- Spectra Optia is faster to use and needs to be done less often than manual red blood cell exchange.
- Automated red blood cell exchange should be considered in patients with sickle cell disease who need regular transfusion
- Cost modelling shows that in most cases using Spectra Optia is cost saving compared with manual red blood cell exchange or top-up transfusion.



American Society for Apheresis (ASFA)

- Guidelines published every 2-3 years
- Comprehensive literature review
- Practical recommendations
- 2019: Padmanabhan, A, et al. 8th Special Edition J Clin Apheresis. 2019; 34: 171– 354.



Improving Quality of Life



**Female university student
age 20:** “Without my
monthly blood exchanges,
my education would be
limited”

**Male Teaching Assistant
age 25:** Having a monthly
blood exchange has given
me the opportunity to
progress in my role and
improve my social activities
with friends.



Automated exchange red cell usage




Adult Red Cell Exchanges -TAS National	2017/18
Patients	137
Procedures	545
Red Cells	4329
Average Red Cells per Patient	32
Average Red Cells per Procedure	8

Paediatric Red Cell Exchanges -TAS National	2017/18
Patients	24
Procedures	76
Red Cells	390
Average Red Cells per Patient	16
Average Red Cells per Procedure	5





Ro red cell units

- Approximately 60% of patients with sickle cell disease require Ro phenotype red cells (cDe)
 - Ro 10 x more common in Black African and Black Caribbean than White ethnic background
- Only 2% blood donors Ro
- Demand for Ro increasing approximately 15% per year
- Effective communication with BT Laboratories and NHSBT and advance notification for planned exchanges. Notify them as soon as possible for emergency exchanges, to help the demand to be managed.



Who are Therapeutic Apheresis Services and how do we contribute to improving access to automated red cell exchange for SCD patients?





NHS
Blood and Transplant
Therapeutic Apheresis Services
Saving and Improving Lives

- Collection and Exchange Apheresis Services
- Extracorporeal Photopheresis
- Lipid Apheresis





8896
Treatments


Caring Expert Quality

1448
Patients






TAS ARCX Activity



How does this look?

- ◆ Work collaboratively with trusts/ services to provide access to ARCX service for patients needing acute or long term transfusion
 - ◆ Assurance of robust service with established national model/ policies and procedures
 - ◆ Regular MDT and patient review meetings to evaluate care
 - ◆ Annual review of service user (clinical teams) satisfaction (74% 2019)
 - ◆ Each TAS unit is fully regulated by the Human Tissue Authority, JACIE, Care Quality Commission
 - ◆ Annual review of patient satisfaction survey (97% 2018)
- 

Examples of existing collaborations



Leeds Teaching Hospitals

559 ARCX
procedures in
5 years

Birmingham and Sandwell Trust

482 ARCX
carried out in
2.5 years.

Manchester Children's Hospital

Newly
established
service 2019

Connect with TAS



Blood and Transplant



<https://www.nhsbt.nhs.uk>



[Google.com/maps](https://www.google.com/maps)



[@NHSBTTAS](https://twitter.com/NHSBTTAS)



[Youtube.com](https://www.youtube.com)



We host an Annual Apheresis Conference
TherapeuticApheresisServices@nhsbt.nhs.uk

Thank you for listening

Any questions?



Acknowledgements

All our NHSBT Therapeutic Apheresis Unit Staff

NHSBT TAS National support

Lydia Ball, Chris Ogle

Kay Harding

Catherine Howell

TAS Consultant

Dr Helen New

Blood Donation

Ebony Laws

For the photographs

Thank you to: Patients, families and TAS Staff .

